CoChat

Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy

Chrousos, George P., Harris, Alan G. · 1998 · Neuroimmunomodulation

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

The safety of long-term inhaled corticosteroid therapy at commonly prescribed doses is an issue of growing concern to physicians and international regulatory bodies. This is so because long-term use of these drugs has become the mainstay of chronic asthma management and their introduction now is widely recommended in official treatment guidelines at the ‘mild persistent’ stage of asthma, where regular daily therapy is first begun. In addition to more frequent use of inhaled corticosteroids, there is a further trend to use higher doses of existing inhaler therapies and to use the newer and more potent compounds that have recently become available. At the same time as these developments have been taking place, there has not been a concurrent move to a more rigorous examination of the safety profile of these inhaled corticosteroid treatments – especially to assess their effects on the hypothalamic-pituitary-adrenal (HPA) axis. Most safety data with respect to HPA axis effects have been derived from testing methods that are limited in their ability to detect HPA system impairment and, more seriously, that can give the impression of functional integrity in the HPA axis when there may be moderate (or even greater) impairment. In this first part of a two-part review of the HPA axis effects of inhaled corticosteroids and of how these effects should be assessed, we examine the currently used and the currently available testing methodologies and also review the present state of knowledge concerning the structure and function of the HPA axis and the effects of its suppression. It is clear that there are state-of-the-art tests to assess in a discriminating manner the safety profile of inhaled corticosteroids. These tests have been insufficiently employed, including during the drug development process, yet they are readily available, relatively inexpensive and can detect adrenal suppression before the appearance of clinical effects. In part 2 of this review we examine what can be learned about the effects of inhaled corticosteroid therapy on the HPA axis from the limited amount of reliable published information from clinical and pharmacological studies describing their use and safety.

Overview

Integrity signals

Registry

Crossref · 10.1159/000026348

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 90 references

Cited by

See all 56

Metadata

Authors
Chrousos, G. P., & Harris, A. G.
Affiliations
National Institutes of Health (US)
Venue
Neuroimmunomodulation
Publisher
S. Karger AG
Published
1998
Volume
5
Issue
6
Pages
277-287
ISSN
  • 1021-7401 (ISSN-L)
  • 1423-0216
OpenAlex
W2048065046
Cited by
50
References
90
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2020: 2 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
1.57
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • NeuroImmunoModulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
hypothalamic-pituitary-adrenal axis, inhaled corticosteroids, adrenal suppression, persistent asthma, drug safety, glucocorticoid adverse effects, mild persistent asthma
MeSH terms
Administration, Inhalation, Adrenal Cortex Hormones, Asthma, Humans, Hypothalamo-Hypophyseal System, Immunosuppression Therapy, Pituitary-Adrenal System, Neuroimmunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy. https://app.cochat.ai/papers/10.1159/000026348
The paper
Chrousos, G. P., & Harris, A. G. (1998). Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy. Neuroimmunomodulation. https://doi.org/10.1159/000026348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.